Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. - Wikidata - awgldk - TriplyDB

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

http://www.wikidata.org/entity/Q37156885

about

Stem cell-based therapies for age-related macular degeneration: current status and prospects Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.Therapeutic effect of oral bisphosphonates on choroidal neovascularization in the human eye.A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.Reduction of choroidal neovascularization in mice by adeno-associated virus-delivered anti-vascular endothelial growth factor short hairpin RNA.Interventions for Age-Related Macular Degeneration: Are Practice Guidelines Based on Systematic Reviews?The business of exploiting induced pluripotent stem cells.Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality.Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization.The estimated prevalence and incidence of late stage age related macular degeneration in the UK Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration.Performance of a computerised visual acuity measurement device in subjects with age-related macular degeneration: comparison with gold standard ETDRS chart measurements Serum MicroRNAs as Potential Biomarkers of AMD Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration The cost-effectiveness of second-eye cataract surgery in the UK Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation Efficacy of Ethanol Extract of Fructus lycii and Its Constituents Lutein/Zeaxanthin in Protecting Retinal Pigment Epithelium Cells against Oxidative Stress: In Vivo and In Vitro Models of Age-Related Macular Degeneration Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis).Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration.Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration.Current status of vascular endothelial growth factor inhibition in age-related macular degeneration.Cost effectiveness of treatments for wet age-related macular degeneration.Genetic predictors of response to photodynamictherapy.Mechanism of inflammation in age-related macular degeneration Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges.Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan.In vivo, in vitro toxicity and in vitro angiogenic inhibition of sunitinib malate.Effects of anti-VEGF agents on rat retinal Müller glial cells.Anti-vascular endothelial growth factor in age-related macular degeneration: puzzle or a silent beginning!Predictable signs of benign course of polypoidal choroidal vasculopathy: based upon the long-term observation of non-treated eyes.Effects of oral bisphosphonates on myopic choroidal neovascularisation over 2 years of follow-up: comparison with anti-VEGF therapy and photodynamic therapy. A pilot study.Kinetics of retinal vaso-obliteration and neovascularisation in the oxygen-induced retinopathy (OIR) mouse model.An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure.Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.

P2860

Q28083236-DDB5EBA3-9396-4ABA-8EB4-1A84FF3C985B Q28292764-F85D2EC4-B1C3-4E80-8D75-29A2AA657926 Q30565636-4446B60C-46C0-4A9E-83B5-4C061BB31117 Q33944980-6C844265-A596-4447-B7A9-7192F9EEFCF1 Q34035522-AC9A9FDF-321A-4DC4-827F-A7161DA0FAAE Q34325559-842F2C5D-8439-48A3-BC46-73846B641288 Q34410824-A4816309-FD9E-4318-B35B-8780D3CBF7BD Q34451693-ACFC18F9-0A82-4419-B6A2-D5E1CEE97073 Q34510579-30D5D7A0-BBDC-4ECA-BDA1-140FE8F69A0D Q35088543-F398C8D5-E41B-4314-BB17-C08E4DD9607B Q35350981-748C6449-4583-4562-A13E-330D6931F06F Q35818087-F9970267-D9C1-400E-9D5E-C6B704DB3B46 Q35897705-AAE7778D-BB1D-41E3-B23E-AB67E19FCBCC Q35923834-C315B64D-BA44-417A-BDEA-21DD72594C32 Q35970082-926CC5DA-49FD-49B1-825A-2E3D477708E3 Q36078404-0F7EA65F-0701-4316-B8B5-CA54C4039F87 Q36088747-82073D5E-DD48-4768-B93C-2550DE330232 Q36208514-FE332615-0DF2-4074-8F74-978C88B55D3C Q36743807-0173884A-7A04-4740-A977-7D29B42DE119 Q36864176-E6EDB3DE-201A-4F3C-BF18-BFF2F594193E Q37218617-A619D57F-7AD0-4C17-8613-5F78025790CB Q37232522-7C666027-6C58-4262-96D6-4AE866222011 Q37246879-7E0B94C1-4ED8-49B4-909F-888920EBB729 Q37356525-E6129141-917C-4780-BFB1-607F12303A25 Q37704339-D1ECDC1F-40F7-458C-8E30-90118C1923F9 Q37829731-F193F523-E767-4E0D-9A05-5F8A82CB5376 Q37931236-21FA8AFF-5505-4632-8C13-290648FF0DA8 Q38064846-3474CC9C-00B7-49F1-B338-F8EB704B8E92 Q38631993-886A1D80-9B05-49F4-9232-8FA3BF4850FE Q39323991-C38D3409-A744-47B0-A804-FE8A5D1D3698 Q39348099-E58F42B1-6524-4585-990D-6447B97FAA9F Q40284780-5E0CFAFA-A1C4-40E4-B736-3B60B2504A65 Q42881794-4B86313B-BA63-4B69-A148-685F1FB72CD9 Q43118890-950E9C4C-7C23-48A2-8137-C9CFFF4106E1 Q45748758-EC5FCDA8-CDC1-499D-BDCC-5958E9C761C4 Q45969448-2FFB4671-BB78-4757-BE07-E0E077F3BE4E Q47123727-64FD91F1-7F27-4939-A9EA-8398ECD7A985 Q53373714-13676E7C-56BF-4171-802D-340A2A794ED8 Q53438701-B9698E60-D0E2-46A0-A22A-6E0340B8855E

P2860

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

http://www.wikidata.org/entity/Q37156885

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ranibizumab and pegaptanib for ...... eview and economic evaluation.

@en

Ranibizumab and pegaptanib for ...... eview and economic evaluation.

@nl

type

label

Ranibizumab and pegaptanib for ...... eview and economic evaluation.

@en

Ranibizumab and pegaptanib for ...... eview and economic evaluation.

@nl

prefLabel

Ranibizumab and pegaptanib for ...... eview and economic evaluation.

@en

Ranibizumab and pegaptanib for ...... eview and economic evaluation.

@nl

P1433

Q37156885-6DCCC838-4A83-4A52-ADE5-6AA813A10E45

P1476

Q37156885-4389A379-5485-48D9-8201-67D07D9119CA

P2093

Q37156885-07C770E5-C1C6-48B9-A071-F1D8693710B6

Q37156885-083C582D-FFA0-42D3-A0FE-6E57A4D1F355

Q37156885-6D2393BB-C329-4362-BF1A-C6B41D10824D

Q37156885-85F2A03D-AC5B-482A-ABD5-30C873B9442E

Q37156885-F2F39ADC-74A8-40A3-B5FA-4EC187D8A7C5

Q37156885-FAEA06AB-17B6-454F-91DF-325352DBC0B4

P304

Q37156885-57F35282-8D6B-4ACF-8901-3EE58DBF6BF4

P31

Q37156885-FAC77325-6312-438B-840F-12DD27167AFA

P356

Q37156885-CA0A21BF-EA01-4996-B352-0E3173BAAB44

P433

Q37156885-1D7238F4-27F0-4EF2-9871-194D4C49D6F7

P478

Q37156885-8292F62B-9674-4F3F-BCB7-CFB343579CB3

P577

Q37156885-9181F3C5-D9E5-4983-8226-123A1B2005B4

P5875

Q37156885-EDE1CCC7-556D-4C30-8308-D4C723AD010C

P698

Q37156885-41A9FF73-EC2F-4DF0-AC0A-B7CFA03735C9

P356

P1433

Health Technology Assessment

P1476

Ranibizumab and pegaptanib for ...... eview and economic evaluation.

@en

P2093

A J Clegg

http://www.w3.org/2001/XMLSchema#string

A Price

http://www.w3.org/2001/XMLSchema#string

A Takeda

http://www.w3.org/2001/XMLSchema#string

J Jones

http://www.w3.org/2001/XMLSchema#string

J L Colquitt

http://www.w3.org/2001/XMLSchema#string

S C Tan

http://www.w3.org/2001/XMLSchema#string

P304

iii-iv, ix-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3310/HTA12160

http://www.w3.org/2001/XMLSchema#string

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5388174

http://www.w3.org/2001/XMLSchema#string

P698

18462575

http://www.w3.org/2001/XMLSchema#string